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Abstract
The objective of the work — is to study the course of HBV-infection in pregnant women, infected and uninfected with HIV,
based on the analysis of clinical-laboratory parameters.
Materials and methods. HBV-infection was diagnosed in 5.6% of women with negative HIV-status and in 9.4% positive with
HIV.
To verify the diagnosis of HBV-infection, the data of anamnesis, clinical examination, laboratory tests: general clinical,
biochemical, EIA, PCR, and VL in each trimester of pregnancy were used.
Results. In HIV-negative pregnant women, 71.6% of the patients were diagnosed with HBsAg carrier status and 28.4% – the
replication stages. Replication stages were only in HIV-positive patients.
The frequency of clinical manifestations of CHB is higher in HIV-positive women – it is 33.33% vs 10.00% in HIV-negative
(p<0.05), in a significantly lower rate of cytolysis – 11.11% vs 45.00% (p<0.001), which did not increase up to the childbirth.
The rate of VL of HBV increased before the childbirth in 63.3% of pregnant women without HIV-infection, and in 36.7% it did
not change. Thus, in 83.3% of HIV-infected, it decreased to the threshold, and in 16.7% it hasn’t changed (p<0.01).
During pregnancy, the immunotolerant phase of CHB in women of both groups was not transformed into immunoactive, and
in HIV-negative pregnant women – the carrier status of HBsAg to the replicative form.
Conclusion. In pregnant women with HIV-infection the incidence of replicative forms of HBV-infection is 3.5 times than in
pregnant women without HIV-infection, the HBsAg carrier status is not determined. HIV-immunosuppression is accompanied
by the prevalence of the immunotolerant phase of CHB (88.9%) with subclinical course without disturbance of pigmentary
metabolism and cytolysis increase against the background of a decrease of VL HBV up to the threshold in 83.3% (p<0.01).
The inverse weak correlation between the level of CD4 + T-lymphocytes and VL HBV was determined.
In HIV-negative pregnancies, latent forms of HBV-infection prevail (71.6%). Replicative forms are characterized by a low
degree (80.0%) of HBV viremia (p<0.05) with minimal cytolysis in 43.3% of women (p<0.001), which did not change during
pregnancy.
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Problem statement and analysis of the
latest research
Under present conditions HBV-infection is one of the most
urgent medical and social problems in many countries of the
modern world, as it is a frequent cause of chronic liver dis-
ease, and in women of childbearing age it can be realized as
perinatal infection. This problem is common to midwives,
infectious disease physicians, pediatricians and requires a
general strategy for the management of a pregnancy in such
women [1, 3, 5]. Knowledge of the natural course of HBV-
infection in pregnant women will help to understand the patho-
genetic mechanisms of its negative impact on maternal and
fetal health. Timely diagnosis of viral hepatitis in pregnant
women, establishing their clinical form is essential for the
prognosis and prevention of obstetric and perinatal complica-
tions.
In recent years an increase in viral hepatitis in pregnant
women co-infected with HIV is observed. In this regard it is
important to study the characteristics of the course of CHB on
the background of HIV-infection.
According to the recommendations of the WHO and the
European Association for the Study of Liver Diseases, preg-
nancy is not contraindicated for the women with HBV-infection
who have not reached the stage of cirrhosis, as well as in the
absence of signs of active inflammatory process in the liver
or cholestasis because it does not have a negative effect on
the course of CHB [5, 8, 9]. The feature of HBV-infection in
HIV-infected pregnant women is the latent course in 32.7-43.9
% [1, 2].
Therefore, a comprehensive clinical and laboratory ex-
amination during pregnancy should play a decisive role in
the formulation and verification of the diagnosis, which will
enable to study the risk factors that contribute to perinatal
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infections of the fetus.
The purpose of the work is to study the course of HBV-
infection in pregnant women infected and uninfected with HIV,
based on the analysis of clinical and laboratory parameters.
1. Materials and Methods
For the period from 2012 to 2017 the progression of HBV-
infection in pregnant women aged 18-35, depending on their
HIV-status was analyzed. Out of the 3762 pregnant women
with negative HIV-status, 211 women infected with HBV were
found, accounting for 5.6 % of the total number of examined
pregnant women. During examination of 192 pregnant women
with positive HIV-status, chronic hepatitis B infection (CHB)
was diagnosed in 18 women, which is accounted for 9.4 %.
For the verification of the diagnosis of HBV-infection with
the establishment of its clinical stage and phase, data from
anamnesis of the disease, clinical examination by organs and
systems, laboratory tests (general and clinical), immunoassay
(ELISA), polymerase chain reaction (PCR), qualitative and
quantitative – viral load (VL), instrumental methods of inves-
tigation (ultrasound of the abdominal cavity of the pregnant
woman) were used. Among the main criteria the indexes of
the replicative activity of the virus and the activity of the in-
flammatory process in the liver according to the indicators
of the content of ALT, AST, bilirubin and its fractions in
serum and thymol samples in each trimester of pregnancy
were evaluated.
The dynamics of these indicators was studied, depending
on the trimester of pregnancy and the degree of HIV-related
immunosuppression.
Women, in which during registration in women’s consul-
tation, HBsAg was detected during initial screening, were
tested for the final diagnosis in the following volume: HBeAg,
anti-HBeAg, anti-HBcor IgM and IgG, anti-HBcor total and
anti-HBsAg by the immunoassay method (ELISA). In re-
peated studies in the dynamics of pregnancy (in the 2nd and
3rd trimesters) anti-HBsAg, anti-HBeAg and anti-HBcor IgG
were detected to exclude acute HB in the recent past. In
women with positive serological markers, HBV DNA was
determined by PCR method – qualitative and quantitative (VL
HBV) in each trimester of pregnancy.
When HBsAg, anti-HBeAg and anti-HBcor IgG were
detected in the absence of other markers of hepatitis and
cytolysis syndrome and at the threshold level of VL HBV
or less than 104 copies/ml, women were verified as HBsAg-
carriers. There were no clinical and anamnestic data before
the pregnancy that could indicate the benefit of HBV-infection
in these women.
The replicative stage of the disease was established based
on the detection of HBsAg, HBeAg, anti-HBcor (total), pos-
itive PCR of HBV DNA and the presence of cytolysis syn-
drome. In 15 (7.1 %) women the replication stages of HBV-
infection with mutated strains were diagnosed, in which other
positive replicating markers were determined in the absence
of HBeAg.
Laboratory examinations of pregnant women with posi-
tive HIV-status were performed on the basis of a centralized
laboratory of diagnosis of HIV-infection, toxoplasmosis, vene-
real diseases and viral hepatitis, certified by the Ministry of
Health of Ukraine, at the Ivano-Frankivsk Oblast Clinical In-
fectious Disease Regional Center for HIV/AIDS Prevention,
and women with negative HIV-status were screened at the
¡¡Synevo¿¿ Laboratory.
The probability of a possible error for each indicator was
determined by the statistical criterion of the Student. The
statistical processing of the results of the research was carried
out on a personal computer using the prevailing database of
surveyed patients in the program ¡¡STATISTICA for Windows
6.0¿¿. The average values (M) were calculated, the average
errors of the arithmetic mean (m). To determine the relation-
ship between values, the Pirson rank correlation method was
used to calculate the correlation coefficient (r).
2. Results and Discussion
Most often among HIV-negative pregnant women HBsAg car-
rying was diagnosed as an integrative stage of HBV-infection
– 151 (71.6 %), significantly rarer replicative stage – 60 (28.4
%): in immune active phase – 27 (45.0 %) and in immune
tolerant phase – 33 (55.0 %) (Table 1).
All HIV-positive pregnant women were diagnosed only
with replication stages: in immune tolerant phase – 16 (88.9
%) and in immune active phase – 2 (11.1 %), HBsAg carrying
was not registered in any case.
The frequency of clinical manifestations of replicative
forms of chronic HBV-infection in pregnant women is pre-
sented in Table 2.
More often there were no complaints during pregnancy
in pregnant women with HIV-negative status in contrast to
women with HIV-positive status – 38.33 % vs 16.67 % (p<0.05).
Among the clinical manifestations of chronic HBV-infection
during the gestation period increased fatigue and decreased
appetite were observed reliably less often in pregnant women
in the first group – 35.00 % and 21.67 % respectively, unlike
in pregnant women in the second group – 61.11 % and 50.00
% respectively (p<0.05).
In women without HIV-infection nausea and periodic
heaviness in the right hypochondrium were also significantly
less common in 23.33 % and 10.00 % respectively, especially
after meals that could be linked to pregnancy, whereas in preg-
nant women with positive HIV-status – 50.00 % and 33.33 %
respectively (p<0.05). These complaints disturbed women
mainly in the 1and 2 trimesters of gestation and until the end
of pregnancy were present only in 10.00 % of pregnant women
in the 1group and 33.33 % in the second group (p<0.05).
Hepatomegaly was observed only in 10.00 % of women
in the 1group in cotrast to 33.33 % in the comparison group
(p<0.05), which is three times more often and may be also
linked to the administration of HAART, smoking, the use
of alcohol and drugs. In all women of the two groups with
the immune active phase of HBV-infection no disturbances
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Table 1. Variants of the course of HBV-infection in pregnant women depending on the HIV-status
The number of pregnant women
Stages and phases of chronic HBV-infection HIV-negative status HIV-positive status
absolute numbers % absolute numbers %
1 HBV-infection: 211 100 18 100
1.1 HBsAg carrying (integration stage) 151 71.6 - -
1.2 replication stage of HBV infection: 60 28.4 18 100
- immune active phase 27 45 2 11.1
- immune tolerant phase 33 55 16 88.9
Table 2. The frequency of clinical manifestations of replicative forms of HBV-infection in pregnant women depending on
HIV-status
Clinical manifestations
Pregnant women
1st group 2nd group
HIV-negative status, n=60 HIV-positive status, n=18
absolute numbers %±m absolute numbers %±m
Increased fatigue 21 35.00±6.16 11 61.11±11.49*
Decreased appetite 13 21.67±5.32 9 50.00±11.79*
Periodic nausea 14 23.33±5.46 9 50.00±11.79*
The heaviness in the right hypochondrium 6 10.00±3.87 6 33.33±11.11*
Hepatomegaly 6 10.00±3.87 6 33.33±11.11*
No complaints 23 38.33±6.28 3 16.67±8.78*
Notes.
* – the probability of discrepancy between indicators in pregnant women of the 1and 2 groups, p<0.05.
of pigmentary metabolism were observed in the presence of
hepatomegaly during the entire gestation period. Normal
indexes of thymol test, absence of hypergammaglobulinemia
indicated also a lack of mesenchymal-inflammatory response
in women of these groups.
It should be noted that not all women were timely screened
in the first trimester of pregnancy: among HIV-negative women
only 70.0 % of women and among HIV-positive women – 61.1
% due to untimely access to women’s consultation and regis-
tration in connection with pregnancy (Table 3).
The minimum degree of cytolysis (ALT = 64.0 ± 2.4 U/l,
AST = 58.0 ± 3.6 U/l) was observed in 43.3 % of women in
the 1st group with the immune active phase of HBV-infection
and in women in the 2nd group only in 11.1 % of cases
throughout the whole gestation period (p<0.001). There was
no marked increase in cytolysis before delivery in women of
both groups, even with a high degree of viremia (VL HBV
>105 copies/ml).
Moderate degree of cytolysis in women with HIV-positive
status was not detected. Only one case (1.7 %) was ob-
served in woman with HIV-negative status during the 2nd-3rd
trimesters of pregnancy on the background of low VL HBV
(1.2 × 102 copies/ml).
During pregnancy cytolysis was not observed in 55.0 %
of women with immune tolerant phase of HBV-infection and
negative HIV-status compared to 88.9 % of pregnant women
with HIV-positive status (p<0.001).
Particular attention should be paid to the fact that the
immune tolerant phase of chronic HBV-infection was not
transformed into immune active throughout the pregnancy in
women of both groups and in women with HIV-negative status
the HBsAg-carrying was not transformed into the replicative
stage.
In pregnant women with HIV-negative status (Table 4) the
replication stage of HBV-infection was usually accompanied
by a low degree of viremia of HBV (VL≤105 copies/ml) with
its growth on 1-2 log in the third trimester compared with the
second trimester – 80.0 % vs. 61.7 % (p<0.05). In women
with HIV-positive status, on the contrary, there was a decrease
in the viral load of HBV before childbirth – low level of
viremia was detected in 61.1 % in the second trimester against
16.7 % in the third trimester (p<0.05).
A high degree of viremia (VL>105 copies/ml) with a
growth on 2-3 log was diagnosed in 16.7 % of pregnant
women of the 1st group in the third trimester compared with
5.0 % in the second trimester (p<0.05). In women of the
second group high degree of viremia was not registered.
In women without HIV-infection threshold degree of viremia
(VL≤750 copies/ml) was significantly more often registered
in the second trimester of pregnancy than in the third trimester
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Table 3. Degree of hepatitis activity in pregnant women with replicative forms of HBV-infection depending on HIV-status
Degree of cytolysis
Terms of examination of pregnant women
1group 2 group
HIV-negative status, n=60 HIV-positive status, n=18
I trimester II trimester III trimester I trimester II trimester III trimester
abs./% abs./% abs./% abs./% abs./% abs./%
Minimum 18/30.0 26/43.3 26/43.3 1/5.5 2/11.1 2/11.1*
Low - - - - - -
Moderate - 1/1.7 1/1.7 - - -
High - - - - - -
Absent 24/40.0 33/55.0 33/55.0 10/55.6 16/88.9 16/88.9*
Total 42/70.0 60/100.0 60/100.0 11/61.1 18/100.0 18/100.0
Notes.
* – the probability of discrepancy between the indicators in pregnant women of the 1and 2groups in the third trimester of pregnancy,
p<0.001.
Table 4. Degree of viremia in pregnant women with replicative forms of HBV-infection depending on the HIV-status
Degree of viremia
Terms of examination of pregnant women
1group 2group
HIV-negative status, n=60 HIV-positive status, n=18
I trimester II trimester III trimester I trimester II trimester III trimester
abs./% abs./% abs./% abs./% abs./% abs./%
≤750 copies/ml 12/20.0 20/33.3 2/3.3 * 6/33.3 7/38.9 15/83.3***•
≤105 copies/ml 15/25.0 37/61.7 48/80.0** 5/ 27.8 11/61.1 3/16.7***•
>105 copies/ml - 03.05.2000 10/16.7** - - -
Total 42/70.0 60/100.0 60/100.0 11/61.1 18/100.0 18/100.0
Notes.
* – the probability of the discrepancy between the indicators in pregnant women of the 1st group in the 2 and 3 trimester of pregnancy,
p<0.01;
** – the probability of the discrepancy between the indicators in pregnant women of the 1group in the second and third trimester of
pregnancy, p<0.05;
*** – the probability of the discrepancy between the indicators in pregnant women of the 2nd group in the 2 and 3 trimester of pregnancy,
p<0.01;
• – the probability of the discrepancy between the indicators in pregnant women of the 1and 2 groups in the third trimester of pregnancy,
p<0.01.
of pregnancy – 33.3 % vs. 3.3 % (p<0.05), which means
that before childbirth it grew. In women with HIV/HBV coin-
fection VL HBV, on the contrary, declined: in the second
trimester of pregnancy the threshold level of the viremia was
registered in 38.9 % of patients and in the third trimester –
83.3 % (p<0.05).
However, in rare cases in women of the 1 group, such
a regularity was not observed. In 2 women (3.3 %), on the
contrary, the low degree of viremia (VL = 104 copies/ml)
in the second trimester decreased to the threshold degree in
the third trimester with normal ALT levels during pregnancy.
It should be noted that in women with HIV-negative status,
in contrast to women with HIV-positive status, the level of
viremia increased before childbirth. In the 3 trimester the
threshold level of the viremia was in 3.3 % of women in
first group against 83.3 % of the second (p<0.01), which is
probably due to the administration of lamivudine, which is
included in the treatment scheme of HIV-infection and at the
same time inhibits the replication of the HBV.
Analyzing the course of hepatitis in women with HIV-
positive status, we took into account the dependence of VL
HBV on the level of HIV-related immunosuppression. The
level of CD4+T-lymphocytes > 500 cells/µl was estimated
as normal, 350-499 cells/µl – moderate immunosuppression,
200-349 cells/µl – expressed immunosuppression,
<200 cells/µl – deep immunodeficiency according to Order
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No. 182 (Table 5).
In pregnant women co-infected with CHB/HIV statisti-
cally insignificant dependence of the VL HBV on the degree
of HIV-immunosuppression (p=0.572) was noted according
to the critical value of the Student’s t-distribution.
The Pearson correlation coefficient is determined between
the two data groups – CD4+T-lymphocytes and VL HBV
in these women. The inverse weak correlation between the
investigated values is established (the correlation coefficient
(r) is -0.142).
In pregnant women with different degree of immunosup-
pression the varying levels of VL HBV were found almost
at the same frequency. Only one woman with VL HBV≤105
copies/ml was in a stage of deep immunodeficiency.
According to the current research data HBV-infection in
pregnant women usually runs in a chronic asymptomatic form
(97.4 %). Therefore, its diagnosis is difficult in pregnant
women. Regarding subclinical forms of replicative HBV-
infection, they are accompanied by asthenic (90.0-93.0 %),
dyspeptic (35.0-40.0 %), mesenchymal-inflammatory (32.0-
36.0 %), cholestatic syndromes (20.0-25.0 %), hepatospleno-
megaly (35.0-40.0 %) and also by insignificant impaired liver
function, manifested with a minimal degree of cytolysis in
50.0-52.0 % of patients [5, 6, 8]. The above data coincide
with the results of our study.
Also, the results of our study, as well as the data of stud-
ies by other authors, indicate that despite the replication of
the virus cytolysis rates remained within the normal range
throughout the pregnancy in part of pregnant women (48.0-
50.0 %). At the same time occasional cases of progressive
deterioration of the liver function up to the development of
fulminant hepatic failure in HBsAg-positive pregnant women
are described in the literature [4, 5, 9].
According to the observations of other authors, during
pregnancy in women with CHB thymol test increases, level
of serum transaminases decreases on the background of nor-
mal level of bilirubin, the amount of blood circulating virus
decreases, which may be observed due to the changes in the
immune reactivity of the body of pregnant women and due to
the increase of estrogens concentration in plasma [6, 7, 8].
Perevertenj L. U. and co-authors (2014) point to a high
replication of the HBV in the first trimester of pregnancy, fol-
lowed by its reduction before delivery in 28.0 % of women [5].
Chuikova K. I. and co-authors (2011), vice versa, investigated
the increase of the level of viral replication to 36 weeks of
gestation, which coincides with our data [6].
In literature available to us we did not find the analysis of
maternal HBV-infection on the background of HIV in preg-
nant women.
3. Conclusions
In pregnant women with HIV-infection the incidence of replica-
tive forms of HBV-infection is 3.5 times higher in comparison
with pregnant women without HIV-infection, the HBsAg-
carrying is not determined. HIV-immunosuppression in preg-
nant women with HIV-infection is accompanied by a predom-
inance of the immune tolerant phase of CHB (88.9 %), which
is characterized by a subclinical course without disturbing
the pigmentary metabolism and the growth of cytolysis be-
fore childbirth on the background of a decrease HBV viremia
to the threshold in 83.3 % of cases (p<0.01). The inverse
weak correlation was established between the level of CD4+T-
lymphocytes and VL HBV.
In pregnant women not infected with HIV, latent forms of
HBV-infection are prevalent in the form of HBsAg carrying
(71.6 %). Replicative forms were characterized by a low
level (80.0 %) of HBV viremia before delivery (p<0.05) with
minimal cytolysis in 43.3 % of women (p<0.001), which did
not change throughout the whole gestation period.
4. Prospects of further research
Prospects of further research will be directed at studying the
risk factors that contribute to perinatal infections of the fetus.
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